Robert Stuver
@NicolaisRobertLymphoma attending @sloan_kettering I Alum: @BIDMC_IM I @UpstateNews I @VillanovaU fan
Similar User
@DameofCoags
@MScordoMD
@syang_md
@AgrimaMianMD
@VankaAnita
@DrFredLocke
@GKaurMD
@PallawiTorkaMD
@BeatrizWills
@BrianShafferMD
@NilooLatifi
@HSystromMD
@KBrag_MD
Also Online First: Valemetostat for patients with relapsed or refractory peripheral T-cell #lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study #lymsm thelancet.com/journals/lanon…
Online First: #Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin #lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study #lymsm thelancet.com/journals/lanon…
Excited to share our latest publication on the genomics of Testicular Large B-Cell Lymphoma — @Hemasphere_EHA @clopezgonz85 @SilviaBea1 - onlinelibrary.wiley.com/doi/full/10.10… 🧵👇🏼 #Lymphoma #Genomics #TLBCL #DLBCL #PCNSL #Hematology #CancerResearch
Active CNS 🧠 disease is a major challenge for #lymphoma pts planned for CAR T cells. CNS bridging #radiotherapy can rapidly cytoreduce these high risk pts. The @MSKCancerCenter initial experience out in @BloodAdvances @MSK_RadOnc ashpublications.org/bloodadvances/…
I’m thrilled that our work reporting the efficacy and unique mechanism of action of romidepsin and duvelisib in T cell lymphoma is out today in @NatureMedicine (rdcu.be/dK2g8). A short thread:
CNS relapse risk in T-cell lymphoma. Development of the CITI score. Great work. All we need now is some way to prevent it from happening….! #lymsm ashpublications.org/bloodadvances/…
An elegant review by @teresa_palomero on T-cell Lymphoma Oncogenesis at #MSKlymphomaCME
A comprehensive review on treating high-risk MCL patients by Anita Kumar #MSKlymphomaCME - High Ki67, TP53mut, blastoid morphology, POD24 - Targeted therapy including BTKi + BCL2inh + antiCD20 - Promising data with CAR-T and BsAbs - Refer early to tertiary centers
Staphylococcus aureus and Sézary syndrome ow.ly/ZSBF50Req9A #lymphoidneoplasia
No difference in PFS & OS with IF- vs IS-RT for intermediate stage Hodgkin lymphoma. No relapse after IS-RT occurred in a theoretical IF-RT field and toxicity was significantly less w IS-RT. Great HD17 analysis by the GHSG RT Panel @ChristianBaues @IJROBP doi.org/10.1016/j.ijro…
Anti-TRBC1 ADCs for the treatment of T cell malignancies nature.com/articles/s4158…
Excited to share first results of unedited CD5 CAR T in r/r T-cell lymphoma from a trial led by @HillLaQuisa and R.Rouce @CAGTHouston Infusions were safe and responses durable, with 2 pts still in CR 5+ years later. Multicenter Phase 2 later this year. sciencedirect.com/science/articl…
Failing Forward in Peripheral T-Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…
New in @JTOonline from Dr @brandon_imber: Intracranial response to #osimertinib is excellent for pts with #EGFR-mutant #NSCLC #lcsm with de novo, previously untx brain metastases. Low local failure rates support upfront osimertinib alone in selected pts. sciencedirect.com/science/articl…
Read here results of a new study on a #ruxolitinib-based regimen as a bridge to transplant for #primaryHemophagocyticLymphohistiocytosis . haematologica.org/article/view/h…
T cell lymphoma mutations power adoptive T cell therapies! Excited to see this published! A true collaboration with friend and colleague @koleroybal and our students @jay__daniels and #julie_garcia. nature.com/articles/s4158…
Rare diseases are not rare for patients who have them. An attempt to synthesize literature on the rare alphabet soups of T-cell lymphomas: SPTCL, ENKTL, HSTCL, MEITL, EATL, and others.
#PeripheralT-CellLymphoma. Review of the clinical management of rare subtypes: #SubcutaneousPanniculitis-likeT-cellLymphoma, #hepatosplenic, and #intestinalT-cellLymphoma, and #extranodalNK/T-cellLymphoma. haematologica.org/article/view/h…
Hematologist-oncologist Dr. Cy R. Wilkins (@cywilkinsmd) spoke about the impact of romiplostim on overall survival in chemotherapy induced thrombocytopenia at a session at #ASH23. @ASH_hematology
CONGRESS #ASH23 @anitajkumarMD highlights role of zanubrutinib, obinutuzumab, and venetoclax in pts with newly diagnosed TP53 mutant MCL from a phase II trial. N=25; Most common ≥Grade 3 TEAE (>10%) =neutropenia (12%); 2-year PFS=72%; OS=75%. #lymsm #lymphoma
United States Trends
- 1. #MMA2024 276 B posts
- 2. Georgia 256 B posts
- 3. ATEEZ SHINES AT MMA 43,6 B posts
- 4. #에이티즈 120 B posts
- 5. Bob Bryar 16,6 B posts
- 6. sohee 35,4 B posts
- 7. 8 OTs 2.341 posts
- 8. SOYEON 18,1 B posts
- 9. Haynes King 12,1 B posts
- 10. Trudeau 168 B posts
- 11. #GoDawgs 12,6 B posts
- 12. Kirby Smart 3.917 posts
- 13. Nebraska 18 B posts
- 14. youngji 54,3 B posts
- 15. Zelensky 120 B posts
- 16. Iowa 26,3 B posts
- 17. GOT7 172 B posts
- 18. #Mafiathon2 1.213 posts
- 19. Brent Key 2.134 posts
- 20. GA Tech 4.059 posts
Who to follow
-
Dr. Jodi Mones
@DameofCoags -
Michael Scordo
@MScordoMD -
Shu Yang
@syang_md -
Agrima Mian
@AgrimaMianMD -
Anita Vanka
@VankaAnita -
Frederick L. Locke
@DrFredLocke -
Gurbakhash Kaur
@GKaurMD -
Pallawi Torka
@PallawiTorkaMD -
Beatriz Wills
@BeatrizWills -
Brian Shaffer
@BrianShafferMD -
Niloo Latifi
@NilooLatifi -
Hannah Systrom
@HSystromMD -
Kevin Braghirol
@KBrag_MD
Something went wrong.
Something went wrong.